OrthoPediatrics (NASDAQ:KIDS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OrthoPediatrics (NASDAQ:KIDS) from a sell rating to a hold rating in a report released on Saturday morning.

Several other equities research analysts also recently commented on the stock. Truist Financial boosted their target price on shares of OrthoPediatrics from $19.00 to $20.00 and gave the company a “hold” rating in a research note on Monday, March 2nd. Canaccord Genuity Group started coverage on shares of OrthoPediatrics in a research report on Wednesday, December 10th. They set a “buy” rating and a $24.00 target price for the company. Needham & Company LLC lifted their price target on shares of OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th. BTIG Research boosted their price target on shares of OrthoPediatrics from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Finally, TD Cowen raised shares of OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

OrthoPediatrics Trading Up 4.0%

Shares of KIDS opened at $18.78 on Friday. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. The stock has a market cap of $474.76 million, a PE ratio of -11.11 and a beta of 1.07. OrthoPediatrics has a 1 year low of $15.28 and a 1 year high of $26.40. The stock has a 50 day simple moving average of $17.77 and a 200-day simple moving average of $18.10.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The business had revenue of $61.61 million for the quarter, compared to analyst estimates of $61.27 million. On average, sell-side analysts predict that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its holdings in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after acquiring an additional 2,561 shares during the last quarter. Caption Management LLC acquired a new stake in OrthoPediatrics in the 3rd quarter valued at about $54,000. BNP Paribas Financial Markets increased its position in OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares in the last quarter. Finally, State of Wyoming raised its stake in shares of OrthoPediatrics by 189.7% in the fourth quarter. State of Wyoming now owns 6,822 shares of the company’s stock worth $121,000 after acquiring an additional 4,467 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.